ERCC1 and lung carcinoma: The International Adjuvant Lung Cancer Trial (IALT) analysis showed that patients with ERCC1 protein negative tumors have better adjuvant cisplatin‐based chemotherapy results compared to patients with ERCC1 protein positive tumors.22